Articles

Luspatercept in lower-risk myelodysplastic syndromes: Belgian real-life data into perspective

BJH - volume 16, issue 2, april 2025

B. Heyrman MD, S. Meers MD, S. Sid MD, K. Van Eygen MD, N. De Beule MD, PhD, M. Clauwaert MD, H. Maes MD, A. Salembier MD, J. Lemmens MD, A. Van De Velde MD, PhD, D. Selleslag MD, J. Bouziotis Msc, N. Put MD, A. De Becker MD, PhD

SUMMARY

This report on the real life use of luspatercept in Belgium, describes data of 77 patients. In the response analysis, 65.8% showed a response to treatment, including 35.4% that reached transfusion independency for a minimum of eight weeks. In the responding group, the duration of treatment was at least 38 weeks in 75% of patients. Reasons to stop treatment were adverse event (16,3%), death (23,3%), no response (34,9%) and disease progression (25,6%). One patient stopped treatment due to pronounced fatigue although having an erythroid response. These data confirm the efficacy of luspatercept and the need for real-life data on quality of life.

(BELG J HEMATOL 2025;16(2):65–9)

Read more

PP33 Targeted next-generation sequencing using a pan-myeloid panel in myelodysplastic neoplasms: implementation in clinical diagnostics

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Froyen PhD, J. Willemse PhD, A. Broekmans , R. Smets , B. Cruys , N. Put MD, V. Madoe , M. Janssen , O. Soepenberg , G. Bries MD, PhD, B. Maes MD, PhD

Read more

P4.05 Utility of next-generation sequencing in clinical practice: 5 cases diagnosed with primary myelofibrosis

BJH - volume 7, issue Abstract Book BHS, january 2016

N. Put MD, B. Maes MD, PhD, R. Achten , K. Deraedt , K. Theunissen MD, V. Madoe

Read more

The cytogenetic and molecular diagnosis of haematological malignancies: an overview of current techniques

BJH - volume 5, issue 1, march 2014

N. Put MD, L. Michaux MD, PhD, P. Vandenberghe MD, PhD

Summary

The presence, number and/or type of chromosomal aberrations represent an independent predictor of prognosis in several haematological disorders. Therefore, (cyto)genetic analysis is now routinely performed in many haematological malignancies. Different techniques are available to detect chromosomal abnormalities. Conventional cytogenetic analysis can be performed, and also interphase fluorescent in situ hybridisation is widely used. In addition, multiplex ligation-dependent probe amplification and more recently analysis by means of different array-platforms have been used in research and routine setting. Newly developed techniques, such as next-generation sequencing are only available for research purposes thus far. All these techniques are complementary, and each technique has its own (dis)advantages.

(BELG J HEMATOL 2014;5(1):3–11)

Read more

Cytogenetic and genomic assessment of selected lymphoproliferative disorders

BJH - volume 5, issue 1, march 2014

N. Put MD, L. Michaux MD, PhD, P. Vandenberghe MD, PhD

Summary

Chronic mature B-cell lymphoproliferative disorders, i.e. B-cell chronic lymphocytic leukaemia and plasma cell dyscrasias such as multiple myeloma, have a variable disease course. Clinical staging systems and several biological parameters have been used to estimate tumour burden and predict prognosis. In addition, cytogenetic aberrations have prognostic significance and are therefore investigated in the routine evaluation of these diseases. In this doctoral study, we evaluated available techniques, which can be applied to detect cytogenetic abnormalities in the routine investigation of chronic lymphocytic leukaemia and multiple myeloma. Next, we characterised cytogenetic entities, in particular translocations involving immunoglobulin genes and the proto-oncogenes BCL2 and MYC and investigated clonal evolution in chronic lymphocytic leukaemia.

(BELG J HEMATOL 2014;5(1):25–30)

Read more